Company Overview and News

 
Trading ideas: OSK Holdings, Hibiscus, Alam Maritim, Muda, Vertice

2018-10-15 thestar.com.my
KUALA LUMPUR: OSK Holdings Bhd , Hibiscus Petroleum Bhd , Alam Maritim Resources Bhd , Muda Holdings Bhd and Vertice Bhd are among the stocks to watch, according to JF Apex Research.
3883 5115 5053 HIPEF 5199

 
Muda Holdings rise on acquisition news

2018-10-15 thestar.com.my
KUALA LUMPUR: Shares of Muda Holdings Bhd rose marginally in early trade Monday on acquisition of stationery distribution firm in Singapore.
3883

 
KLCI seen holding on to gains, support at 1,730

2018-10-14 theedgemarkets
KUALA LUMPUR (Oct 15): The FBM KLCI is seen holding on to its gains today, in line with the rebound at most global markets last Friday, with support seen at the 1,730-point level.
3883 5115 5053 HIPEF 5199

 
OSK Holdings, FGV Holdings, Hibiscus Petroleum, Alam Maritim, Muda Holdings, Vertice and MyEG

2018-10-12 theedgemarkets
KUALA LUMPUR (Oct 12): Based on corporate announcements and news flow today, stocks in focus on Monday (Oct 15) may include OSK Holdings Bhd, FGV Holdings Bhd, Hibiscus Petroleum Bhd, Alam Maritim Resources Bhd, Muda Holdings Bhd, Vertice Bhd and MyEG Services Bhd.
3883 5115 5053 HIPEF 5199

 
Muda Holdings buys stationery distribution firm in S'pore for RM4.3m

2018-10-12 theedgemarkets
KUALA LUMPUR (Oct 12): Muda Holdings Bhd is acquiring a stationery distribution company in Singapore for S$1.42 million (RM4.26 million) to strengthen its market position there.
3883 BSMAF 1818

 
Muda Holdings eyes another record profit in 2018

2018-09-24 theedgemarkets
KUALA LUMPUR: Muda Holdings Bhd expects to register another record profit this year, thanks to the continued healthy demand for packaging and paper on the back of reasonable and stable selling prices.
3883

 
Asia File 1QFY19 earnings below expectations

2018-09-04 theedgemarkets
Asia File Corp Bhd (Sept 3, RM2.64) Downgrade to sell with a lower target price of RM2.21: Asia File Corp Bhd’s earnings for first quarter of financial year 2019 (1QFY19) fell below our expectations. Asia File reported a sluggish 1QFY19 net profit of RM8 million, a 44% decline year-on-year (y-o-y) and 29% decline quarter-on-quarter (q-o-q), which made up only 15% of our full-year estimates. Its margins were weaker with earnings before interest, taxes, depreciation and amortisation and net profit margins at 12.
3883 7129

 
Muda Holdings 2Q net profit almost triples to RM11.49m

2018-08-21 theedgemarkets
KUALA LUMPUR (Aug 21): Corrugated carton maker Muda Holdings Bhd's net profit almost tripled to RM11.49 million in the second quarter ended June 30, 2018 (2QFY18) from RM4.13 million a year ago, on lower cost of waste paper and higher selling price of industrial paper, coupled with better selling price of paper packaging products.
3883

 
Muda may rebound further, says RHB Retail Research

2018-08-14 theedgemarkets
KUALA LUMPUR (Aug 14): RHB Retail Research said Muda Holdings Bhd may rebound further after it tested the RM1.73 support in recent trading sessions.
3883

 
KLCI pares gains as decliners overtake advancers

2018-08-10 theedgemarkets
KUALA LUMPUR (Aug 10): The FBM KLCI pared some of its gains at midday today as decliners overtook advancers, tracking the sentiment at most regional markets.
SPMXF UPBMF 7036 5681 BATS 4162 7765 5015 2089 5014 0131 6033 2593 2852 0143 5029 PNADF SPMXY 3883 0026 MYPRY PNAGF GEBHF

 
KLCI starts flat, tracks volatile regional peers

2018-07-06 theedgemarkets
KUALA LUMPUR (July 6): The FBM KLCI opened flat this morning, tracking nervy regional markets, ahead of the U.S. deadline to commence to trade tariffs against China.
MLYBY MLYNF UPBMF 2089 7055 7277 1155 KLKBY 2445 3883 5347 TNABY 2836 TNABF

 
KLCI turns negative as trade war anxiety weighs

2018-07-05 theedgemarkets
KUALA LUMPUR (July 5): The FBM KLCI turned negative at midday break today in tandem with most regional markets, on investors’ anxiety ahead of the Friday deadline for additional U.S. tariffs on Chinese products.
PBLOF MLYBY SPMXF MLYNF UPBMF BATS 4162 1163 1295 2089 9334 0023 1155 5139 SPMXY 3883 3301 0900 0026 1899 2836 3719

 
KLCI hovers above 1,690-level amid choppy trade

2018-07-05 theedgemarkets
KUALA LUMPUR (July 5): The FBM KLCI hovered above the 1,690-level at mid-morning today, amid some choppy trade as regional markets stayed anxious.
HLFBF PBLOF MLYBY MLYNF UPBMF 1082 1295 3794 2089 1155 KLKBY 2445 3883 4863 6888 5819 AXXTF MYTEF

 
The Week Ahead: Awaiting Cabinet line-up and new Umno president

2018-07-03 theedgemarkets
THE ringgit, which last week breached the psychological RM4 mark against the US dollar for the first time in five months, is in the spotlight again. At the time of writing last Friday (June 22), the ringgit fetched 4.0022 against the greenback. The ringgit’s fair value should be 3.80, Prime Minister Tun Dr Mahathir Mohamad told Bloomberg in a June 22 interview. “We would like to strengthen our ringgit, but it should be done naturally,” he said.
SARKF MLYNF 8664 6521 7237 1171 5158 8583 0012 4898 3883 5126 7229 SMEBF 5703 MYTEF MLYBY 4197 5202 7164 5222 1155 4588 4863 3158 4723

14
The Week Ahead: Awaiting Cabinet line-up and new Umno president

2018-06-25 theedgemarkets
The ringgit, which last week breached the psychological RM4 mark against the US dollar for the first time in five months, is in the spotlight again. At the time of writing last Friday (June 22), the ringgit fetched 4.0022 against the greenback. The ringgit’s fair value should be 3.80, Prime Minister Tun Dr Mahathir Mohamad told Bloomberg in a June 22 interview. “We would like to strengthen our ringgit, but it should be done naturally,” he said.
SARKF MLYNF 8664 6521 7237 1171 5158 8583 0012 4898 3883 5126 7229 SMEBF 5703 MYTEF MLYBY 4197 5202 7164 5222 1155 4588 4863 3158 4723

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...